Cite

HARVARD Citation

    De Meulenaere, A. et al. (2021). An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma. Clinical and translational science. 14 (6), pp. 2300-2313. [Online]. 
  
Back to record